A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19 by Keisuke Nakamura, Katsukuni Fujimoto, Chihiro Hasegawa, Ikuo Aoki, Hiroyuki Yoshitsugu, Hiroyuki Ugai, Naoyoshi Yatsuzuka, Yoshiyuki Tanaka, Kenichi Furihata, Brian M. Maas, Prachi K. Wickremasingha, Kelly E. Duncan, Marian Iwamoto, Selwyn A. Stoch, Naoto Uemura

Connect to this object online.